Cargando…
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors di...
Autores principales: | Perez, Marco, Muñoz-Galván, Sandra, Jiménez-García, Manuel P., Marín, Juan J., Carnero, Amancio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747352/ https://www.ncbi.nlm.nih.gov/pubmed/26528855 |
Ejemplares similares
-
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023) -
CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013) -
Mutation testing in melanoma families: INK4A, CDK4 and INK4D
por: Newton Bishop, J A, et al.
Publicado: (1999) -
CDK6 Degradation Is Counteracted by p16(INK4A) and p18(INK4C) in AML
por: Schmalzbauer, Belinda S., et al.
Publicado: (2022) -
P1412: UNCOUPLING INK4 PROTEINS FROM CDK4/CDK6 IN HEMATOPOIETIC STEM CELLS
por: Schirripa, A., et al.
Publicado: (2022)